No Connection between Osteoporosis Drugs and Lower Incidence of Breast Cancer
Published By : 13 Aug 2014 | Published By : QYRESEARCH
According to research carried out at UC San Francisco, it was concluded that as against the popular thought, women can’t be protected from breast cancer by consuming osteoporosis drugs. It was earlier observed that women who took osteoporosis drugs were less likely to contract breast cancer.
However, through clinical trials and assessment of effect of the two most widely consumed drugs for osteoporosis - Reclast and Fosamax, it was inferred that neither drug reduced the chances of breast cancer in women. Researchers found out that low estrogen is perhaps the dominant factor that brought down the incidence of breast cancer and there was minimal connection between administering osteoporosis drugs and lower incidence of breast cancer.
Weakening of bones and protection against breast cancer is mainly driven by low estrogen levels, which is why osteoporosis drugs are prescribed to women. Post menopausal women suffering from osteoporosis generally have low estrogen levels. There exists a direct relationship between estrogen levels and the risk of breast cancer.
It has been advised by doctors that women should not take osteoporosis drugs with a view to decreasing their chances of breast cancer and in order to reduce the possibility of fractures, post menopausal women should continue taking these drugs.
Two clinical trials with placebo controls were conducted, and it was observed that women who received osteoporosis drugs, also known as bisphosphonates, had marginally greater but statistically non-significant chances of breast cancer.
In all the clinical trials, women with a family history of breast cancer were excluded.